search
Back to results

Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes (ReDUCe)

Primary Purpose

Type 1 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring
Continuous Glucose Monitoring (CGM)
Sponsored by
Albert Einstein College of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Type 1 Diabetes focused on measuring diabetes, diabetes distress, young adult, cognitive behavioral therapy

Eligibility Criteria

18 Years - 35 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • T1D duration ≥6 months
  • 18-30 years old
  • HbA1c ≥7.5-14%
  • English- or Spanish-speaking
  • Diabetes Distress
  • Stable insulin treatment regimen (insulin prescription, use of pump, etc.) for at least 3 months prior to study enrollment.

Exclusion Criteria:

  • Comorbid psychiatric condition, including depression, anxiety, or suicidality, which may be independently associated with the main outcomes of diabetes distress or glycemic control. Comorbid psychiatric conditions listed above are being excluded because CBT-DD currently centers on mitigating specifically diabetes distress to improve glycemic outcomes.
  • In treatment for a psychological condition within the last 6 months
  • On a non-stable dose of a psychiatric medication over the past 2 months
  • Developmental or sensory disability interfering with participation
  • Current pregnancy, as self-management and glycemic goals differ
  • Participations in another behavioral intervention study

Sites / Locations

  • Albert Einstein College of MedicineRecruiting
  • Yeshiva UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring

Continuous Glucose Monitoring (CGM) Only

Arm Description

Participants randomized to this arm will receive Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD), enhanced by review of Continuous Glucose Monitoring (CGM) data. Participants will wear study-supplied CGM for the first 6 months of their participation in the trial.

Participants randomized to receive Continuous Glucose Monitoring (CGM) will continue to receive their usual care and will also wear CGM throughout the first 6 months of their participation in the trial.

Outcomes

Primary Outcome Measures

Diabetes Distress Levels
The Problem Areas in Diabetes (PAID) scale will be administered

Secondary Outcome Measures

Hemoglobin A1c
Hemoglobin A1c (HbA1c) values will be calculated from mailed kits for home collection and analysis by a central laboratory.
Time in Range (TIR) calculated from Continuous Glucose Monitoring (CGM)
Percent of time with glucose values between 70-180 mg/dl will be calculated from CGM wear in the 3 months after randomization.
Time Below Range (TBR) calculated from Continuous Glucose Monitoring (CGM)
Percent of time with glucose values below 70 mg/dl will be calculated from CGM wear in the 3 months after randomization.
Time Above Range (TAR) calculated from Continuous Glucose Monitoring (CGM)
Percent of time with glucose values above 180 mg/dl will be calculated from CGM wear in the 3 months after randomization.
Coefficient of Variation (CV) calculated from Continuous Glucose Monitoring (CGM)
The CV is the standard deviation of glucose changes divided by the mean glucose value

Full Information

First Posted
July 26, 2021
Last Updated
May 15, 2023
Sponsor
Albert Einstein College of Medicine
Collaborators
Juvenile Diabetes Research Foundation, DexCom, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05000021
Brief Title
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
Acronym
ReDUCe
Official Title
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 27, 2022 (Actual)
Primary Completion Date
March 31, 2025 (Anticipated)
Study Completion Date
March 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Albert Einstein College of Medicine
Collaborators
Juvenile Diabetes Research Foundation, DexCom, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This project proposes to use telemedicine-delivered cognitive-behavioral therapy (CBT) enhanced with continuous glucose monitor (CGM) review to target diabetes distress in young adults with type 1 diabetes. The efficacy of CBT for diabetes distress (CBT-DD) will be tested in comparison to commercial FDA-approved CGM only in a randomized controlled clinical trial. The investigators central hypothesis is that the addition of a CBT intervention that targets diabetes distress and self-management directly will yield clinically significant improvements in both diabetes distress and glycemic control relative to CGM alone. The investigators propose to recruit 150 young adults (age 18-35) with type 1 diabetes from a national population for an entirely virtual 6-month study over four years, with targeted recruitment of racial/ethnic minorities. In addition to standard measurement of HbA1c for glycemic control and validated patient-reported outcome (PRO) surveys, the investigators plan to innovatively integrate momentary psychological and behavioral data via smartphone-based ecological momentary assessment with CGM data to assess day-to-day changes in diabetes distress, affect, self-management, and glycemia over the course of the trial.
Detailed Description
The investigators propose a randomized controlled trial (RCT) of CBT-DD, enhanced by CGM feedback. The study period will last for 6 months, with the first 3 months on CGM and consisting of a 2-week run-in period prior to randomization, in which EMA (ecological momentary assessment) data will be collected daily, followed by an 8-week CBT intervention period in which EMA data will be collected weekly surrounding CBT sessions, with a subsequent 2-week period post-intervention in which EMA data will again be collected daily. Both intervention and control groups will be doing the same EMA and CGM procedures to enable matching data for comparison. Follow-up virtual study data collection will occur at 3, 6, 9, and 12 months to assess the primary outcome of HbA1c and durability of intervention effect on diabetes distress and HbA1c. Participants in both arms will be provided a sufficient supply of CGM sensors to track their blood glucose daily, throughout the first 6 months of the study. If participants already have personal CGM, they will replace with study-supplied CGM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
diabetes, diabetes distress, young adult, cognitive behavioral therapy

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring
Arm Type
Experimental
Arm Description
Participants randomized to this arm will receive Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD), enhanced by review of Continuous Glucose Monitoring (CGM) data. Participants will wear study-supplied CGM for the first 6 months of their participation in the trial.
Arm Title
Continuous Glucose Monitoring (CGM) Only
Arm Type
Active Comparator
Arm Description
Participants randomized to receive Continuous Glucose Monitoring (CGM) will continue to receive their usual care and will also wear CGM throughout the first 6 months of their participation in the trial.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring
Intervention Description
CBT-DD consists of approximately 10 individual sessions of CBT delivered virtually by trained protocol therapists, conducted over the course of approximately 12 weeks. The CBT-DD consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. CBT-DD sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
Intervention Type
Device
Intervention Name(s)
Continuous Glucose Monitoring (CGM)
Intervention Description
Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing diabetes distress, along with self-management information and treatment options to discuss with providers will also be provided.
Primary Outcome Measure Information:
Title
Diabetes Distress Levels
Description
The Problem Areas in Diabetes (PAID) scale will be administered
Time Frame
3 month mark (post-intervention)
Secondary Outcome Measure Information:
Title
Hemoglobin A1c
Description
Hemoglobin A1c (HbA1c) values will be calculated from mailed kits for home collection and analysis by a central laboratory.
Time Frame
3 month mark (post-intervention)
Title
Time in Range (TIR) calculated from Continuous Glucose Monitoring (CGM)
Description
Percent of time with glucose values between 70-180 mg/dl will be calculated from CGM wear in the 3 months after randomization.
Time Frame
3 month mark (post-intervention)
Title
Time Below Range (TBR) calculated from Continuous Glucose Monitoring (CGM)
Description
Percent of time with glucose values below 70 mg/dl will be calculated from CGM wear in the 3 months after randomization.
Time Frame
3 month mark (post-intervention)
Title
Time Above Range (TAR) calculated from Continuous Glucose Monitoring (CGM)
Description
Percent of time with glucose values above 180 mg/dl will be calculated from CGM wear in the 3 months after randomization.
Time Frame
3 month mark (post-intervention)
Title
Coefficient of Variation (CV) calculated from Continuous Glucose Monitoring (CGM)
Description
The CV is the standard deviation of glucose changes divided by the mean glucose value
Time Frame
3 month mark (post-intervention)
Other Pre-specified Outcome Measures:
Title
Diabetes Distress Levels
Description
The Problem Areas in Diabetes (PAID) scale will be administered
Time Frame
6 month mark
Title
Diabetes Distress Levels
Description
The Problem Areas in Diabetes (PAID) scale will be administered
Time Frame
9 month mark
Title
Diabetes Distress Levels
Description
The Problem Areas in Diabetes (PAID) scale will be administered
Time Frame
12 month mark
Title
Hemoglobin A1c
Description
Hemoglobin A1c (HbA1c) values will be calculated from mailed kits for home collection and analysis by a central laboratory.
Time Frame
6 month month mark
Title
Hemoglobin A1c
Description
Hemoglobin A1c (HbA1c) values will be calculated from mailed kits for home collection and analysis by a central laboratory.
Time Frame
9 month month mark
Title
Hemoglobin A1c
Description
Hemoglobin A1c (HbA1c) values will be calculated from mailed kits for home collection and analysis by a central laboratory.
Time Frame
12 month month mark

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: -Diabetes Distress Exclusion Criteria: Comorbid psychiatric condition (e.g. depression, anxiety, or suicidality). In treatment for a psychological condition within the last 6 months On a non-stable dose of psychiatric medication over the past 2 months Developmental or sensory disability interfering with participation Current pregnancy, as self-management and glycemic goals differ Participations in another behavioral intervention study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shivani Agarwal, MD, MPH
Phone
844-556-6683
Ext
32
Email
Shivani.agarwal@einsteinmed.org
First Name & Middle Initial & Last Name or Official Title & Degree
Jeffrey Gonzalez, PhD
Phone
646-592-4376
Email
jeffrey.gonzalez@yu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shivani Agarwal, MD, MPH
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jeffrey Gonzalez, PhD
Organizational Affiliation
Yeshiva University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Albert Einstein College of Medicine
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shivani Agarwal, MD, MPH
Phone
844-556-6683
Ext
32
Email
shivani.agarwal@einsteinmed.org
First Name & Middle Initial & Last Name & Degree
Shivani Agarwal, MD, MPH
Facility Name
Yeshiva University
City
New York
State/Province
New York
ZIP/Postal Code
10033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeffrey Gonzalez, PhD
Phone
646-592-4376
Email
jeffrey.gonzalez@yu.edu
First Name & Middle Initial & Last Name & Degree
Jeffrey Gonzalez, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27879358
Citation
Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016 Dec;39(12):2126-2140. doi: 10.2337/dc16-2053. No abstract available. Erratum In: Diabetes Care. 2017 Feb;40(2):287. Diabetes Care. 2017 May;40(5):726.
Results Reference
background
PubMed Identifier
10842426
Citation
Arnett JJ. Emerging adulthood. A theory of development from the late teens through the twenties. Am Psychol. 2000 May;55(5):469-80.
Results Reference
background
PubMed Identifier
22025785
Citation
Peters A, Laffel L; American Diabetes Association Transitions Working Group. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society). Diabetes Care. 2011 Nov;34(11):2477-85. doi: 10.2337/dc11-1723. No abstract available. Erratum In: Diabetes Care. 2012 Jan;35(1):191.
Results Reference
background
PubMed Identifier
30657336
Citation
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019 Feb;21(2):66-72. doi: 10.1089/dia.2018.0384. Epub 2019 Jan 18. Erratum In: Diabetes Technol Ther. 2019 Apr;21(4):230.
Results Reference
background
PubMed Identifier
25998289
Citation
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015 Jun;38(6):971-8. doi: 10.2337/dc15-0078.
Results Reference
background
PubMed Identifier
25562264
Citation
Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon RJ, Metcalfe W, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Sattar NA, Traynor JP, Colhoun HM; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015 Jan 6;313(1):37-44. doi: 10.1001/jama.2014.16425.
Results Reference
background
PubMed Identifier
22150528
Citation
Rhodes ET, Prosser LA, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus. Diabet Med. 2012 Apr;29(4):453-63. doi: 10.1111/j.1464-5491.2011.03542.x.
Results Reference
background
PubMed Identifier
28245334
Citation
Dabelea D, Stafford JM, Mayer-Davis EJ, D'Agostino R Jr, Dolan L, Imperatore G, Linder B, Lawrence JM, Marcovina SM, Mottl AK, Black MH, Pop-Busui R, Saydah S, Hamman RF, Pihoker C; SEARCH for Diabetes in Youth Research Group. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA. 2017 Feb 28;317(8):825-835. doi: 10.1001/jama.2017.0686.
Results Reference
background
PubMed Identifier
11522695
Citation
Bryden KS, Peveler RC, Stein A, Neil A, Mayou RA, Dunger DB. Clinical and psychological course of diabetes from adolescence to young adulthood: a longitudinal cohort study. Diabetes Care. 2001 Sep;24(9):1536-40. doi: 10.2337/diacare.24.9.1536.
Results Reference
background
PubMed Identifier
12663572
Citation
Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HA. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003 Apr;26(4):1052-7. doi: 10.2337/diacare.26.4.1052.
Results Reference
background
PubMed Identifier
23952498
Citation
Johnson B, Elliott J, Scott A, Heller S, Eiser C. Medical and psychological outcomes for young adults with Type 1 diabetes: no improvement despite recent advances in diabetes care. Diabet Med. 2014 Feb;31(2):227-31. doi: 10.1111/dme.12305. Epub 2013 Sep 19.
Results Reference
background
PubMed Identifier
28874224
Citation
Rodwell L, Romaniuk H, Nilsen W, Carlin JB, Lee KJ, Patton GC. Adolescent mental health and behavioural predictors of being NEET: a prospective study of young adults not in employment, education, or training. Psychol Med. 2018 Apr;48(5):861-871. doi: 10.1017/S0033291717002434. Epub 2017 Sep 6.
Results Reference
background
Citation
2014 Diabetes Health Care Cost Institute Utilization Report. Health Care Cost Institute. Published 2014. Accessed October 3, 2021. https://healthcostinstitute.org/images/easyblog_ articles/276/HCCI-2017-Health-Care-Cost-and-Utilization-Report-02.12.19.pdf
Results Reference
background
PubMed Identifier
25906787
Citation
Sequeira PA, Pyatak EA, Weigensberg MJ, Vigen CP, Wood JR, Ruelas V, Montoya L, Cohen M, Speer H, Clark S, Peters AL. Let's Empower and Prepare (LEAP): Evaluation of a Structured Transition Program for Young Adults With Type 1 Diabetes. Diabetes Care. 2015 Aug;38(8):1412-9. doi: 10.2337/dc14-2577. Epub 2015 Apr 23.
Results Reference
background
PubMed Identifier
29351961
Citation
Pyatak EA, Carandang K, Vigen CLP, Blanchard J, Diaz J, Concha-Chavez A, Sequeira PA, Wood JR, Whittemore R, Spruijt-Metz D, Peters AL. Occupational Therapy Intervention Improves Glycemic Control and Quality of Life Among Young Adults With Diabetes: the Resilient, Empowered, Active Living with Diabetes (REAL Diabetes) Randomized Controlled Trial. Diabetes Care. 2018 Apr;41(4):696-704. doi: 10.2337/dc17-1634. Epub 2018 Jan 19.
Results Reference
background
PubMed Identifier
31244396
Citation
Bakhach M, Reid MW, Pyatak EA, Berget C, Cain C, Thomas JF, Klingensmith GJ, Raymond JK. Home Telemedicine (CoYoT1 Clinic): A Novel Approach to Improve Psychosocial Outcomes in Young Adults With Diabetes. Diabetes Educ. 2019 Aug;45(4):420-430. doi: 10.1177/0145721719858080. Epub 2019 Jun 27.
Results Reference
background
PubMed Identifier
7555499
Citation
Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, Schwartz CE. Assessment of diabetes-related distress. Diabetes Care. 1995 Jun;18(6):754-60. doi: 10.2337/diacare.18.6.754.
Results Reference
background

Learn more about this trial

Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

We'll reach out to this number within 24 hrs